HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting the renin angiotensin system in dialysis patients.

Abstract
Patients on chronic dialysis therapy have a dramatic excess cardiovascular risk compared to any other population, including those with overt diabetic nephropathy. Despite this, patients on dialysis are almost invariably excluded from trials evaluating the cardioprotective effect of novel treatments. Consistent evidence is available that inhibitors of the renin-angiotensin system, such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), are more cardioprotective than other antihypertensive agents in patients with chronic renal disease or diabetes (with or without renal involvement), but whether this applies also to patients on dialysis is unknown. However, clear evidence is available that ACE inhibitors and ARBs reduce morbidity and mortality in patients on dialysis with heart failure (HF) or atrial fibrillation (AF). Moreover, these drugs may preserve residual renal function in those with preterminal kidney failure as well as vascular access and peritoneal membrane function in those on extracorporeal or peritoneal dialysis, respectively. These drugs also show an excellent tolerability profile in this population. Thus, ACE inhibitors and ARBs are indicated in patients on dialysis with HF or AF. Available evidence suggests that they should be first-choice therapy in patients on dialysis with hypertension, though trials are still needed to formally demonstrate their superior cardioprotective effect over other antihypertensives in this population.
AuthorsPaolo Cravedi, Giuseppe Remuzzi, Piero Ruggenenti
JournalSeminars in dialysis (Semin Dial) 2011 May-Jun Vol. 24 Issue 3 Pg. 290-7 ISSN: 1525-139X [Electronic] United States
PMID21682771 (Publication Type: Journal Article, Review)
Copyright© 2011 Wiley Periodicals, Inc.
Chemical References
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Cytokines
Topics
  • Angiotensin Receptor Antagonists (therapeutic use)
  • Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
  • Cardiovascular Diseases (etiology, prevention & control)
  • Clinical Trials as Topic
  • Cytokines (metabolism)
  • Humans
  • Kidney Failure, Chronic (complications, drug therapy, mortality)
  • Peritoneal Fibrosis (prevention & control)
  • Renal Dialysis
  • Renal Insufficiency (complications, drug therapy, mortality)
  • Renin-Angiotensin System (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: